Intraabdominal infusion of paclitaxel in treating malignant ascites of gastric cancer: report of 6 cases
- VernacularTitle:紫杉醇腹腔灌注治疗胃癌恶性腹腔积液6例报道
- Author:
Xiaoyan YANG
;
Yufen ZHU
;
Haiping ZOU
;
Xianzhi GUO
;
Yuanyuan XIE
;
Jiliang YIN
;
Shengxiang DONG
- Publication Type:Journal Article
- Keywords:
gastric cancer;
paclitaxel;
ascites
- From:
China Oncology
2010;20(2):147-150
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose: Paclitaxel is believed to be efficient in treating malignant ascites in gastric cancer. However, researches are still needed to get more evidence. The aim of this study was to discuss the efficacy and safety of the treatment of malignant ascites in gastric cancer with paclitaxel. Methods: Six cases of late phase gastric cancer patients were enrolled into the study, paclitaxel 60 mg/m~2 and 1 500-2 000 mL natural solution were administered via intraperitoneal injection, qw, for a of total 2-4 weeks. Efficacy and toxicity were determined according to WHO criteria. Results: Five (5/6) had complete response, and one (1/6) with partial response. The malignant ascites recession time was 0.5-10 months, overall survival time 2-10 months, 4 cases suffered grade Ⅰ-Ⅲabdominal pain, 4 cases grade Ⅰ leucopenia, 3 cases grade Ⅰ hair loss, 1 case grade Ⅰ liver injury (with past history of hepatitis). Conclusion: Paclitaxel is effective and relatively safe to treat malignant ascites of gastric cancer.
